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ABSTRACT
The selective and potent inhibition of mitochondrial
translation in Saccharomyces cerevisiae by penta-
midine suggests a novel antimicrobial action for
this drug. Electrophoresis mobility shift assay, T1
ribonuclease footprinting, hydroxyl radical footprint-
ing and isothermal titration calorimetry collectively
demonstrated that pentamidine non-specifically
binds to two distinct classes of sites on tRNA. The
binding was driven by favorable entropy changes
indicative of a large hydrophobic interaction, sug-
gesting that the aromatic rings of pentamidine are
inserted into the stacked base pairs of tRNA helices.
Pentamidine binding disrupts the tRNA secondary
structure and masks the anticodon loop in the
tertiary structure. Consistently, we showed that
pentamidine specifically inhibits tRNA aminoacyla-
tion but not the cognate amino acid adenylation.
Pentamidine inhibited protein translation in vitro
with an EC50 equivalent to that binds to tRNA and
inhibits tRNA aminoacylation in vitro, but drastically
higher than that inhibits translation in vivo, support-
ing the established notion that the antimicrobial
activity of pentamidine is largely due to its selective
accumulation by the pathogen rather than by the
host cell. Therefore, interrupting tRNA aminoacyla-
tion by the entropy-driven non-specific binding is an
important mechanism of pentamidine in inhibiting
protein translation, providing new insights into the
development of antimicrobial drugs.
INTRODUCTION
Pentamidine, an aromatic diamidine, has a long history of
involvement in the treatment of human protozoan
infections (1), and is currently still the clinical drug of
choice against African trypanosomiasis, antimony resis-
tant leishmaniais and Pneumocystis carinii pneumonia
(PCP) (2–4). PCP is an opportunistic infection in patients
with acquired immune deﬁciency syndrome (AIDS) and
other immunocomprised states (5). The selective accumu-
lation of pentamidine and other diamidines by the
pathogen, rather than the host cell, is a major reason for
the drug selectivity; furthermore, acquired resistance is
frequently the result of changes in the transmembrane
transport of the drug (6,7). Despite its broad proﬁle of
antimicrobial activity, the use of this drug is limited
because of its side eﬀects, including nephrotoxicity (1,8).
The incidence of kidney toxicity with parenteral pentami-
dine therapy is quite high, although the damage from this
side eﬀect is reversible (9,10).
Several mechanisms have been suggested for pentami-
dine action against diﬀerent microbes, but the precise
mechanism of its action and its major macromolecular
targets have not been entirely elucidated (11–16).
Pentamidine has been found to precipitate with DNA,
RNA and nucleotides (17). However, only its action in
binding to DNA has received a large attention in the past
decades (18,19). It has been shown that pentamidine
selectively binds to the AT-rich region of duplex DNA
(20–22), but the antimicrobial eﬀect of pentamidine and its
derivatives does not correlate well with their DNA-
binding activity (23). Some proteins may be targets of
pentamidine as well: The drug inhibits the in vitro
activities of topoisomerase from P. carinii and African
trypanosomes (11,13). In addition, pentamidine inhibits
PRL (Phosphatase of Regenerating Liver) activity and the
growth of WM9 human melanoma tumors in nude mice,
coincident with the induction of tumor cell necrosis (24).
However, the activity of TcPRL-1 from Trypanosoma
cruzi was not aﬀected by pentamidine (25). Pentamidine
also demonstrates its activity in selectively modifying
ubiquitin (26).
Pentamidine inhibition of RNA function began to draw
attention in the last decade. It was ﬁrst shown to strongly
inhibit self-splicing of the nuclear group I introns present
in the rRNA genes of P. carinii (27,28), in the 26S rRNA
gene of Candida albicans (29) and in the protein coding
genes of the mitochondrial genome S. cerevisiae (30).
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splicing has been attributed to its binding of the catalytic
intron RNA and its alteration of the intron folding (31).
Pentamidine was also unexpectedly shown to speciﬁcally
and potently inhibit the mitochondrial translation in
S. cerevisiae at a concentration three orders of magnitude
lower than erythromycin, while keeping cytoplasmic
translation unaﬀected. The underlying mechanism of this
important ﬁnding is not clear yet.
The majority of antibiotic classes that are used in the
clinical setting target the ribosomes to inhibit pathogen
translation (32). Appreciation of the high-resolution
ribosome structures and their complexes with antibiotics
suggests that many naturally occurred antibiotics inhibit
bacterial translation through intimate contacts with the
ribosomal RNA (33,34). Aminoglycoside antibiotics that
speciﬁcally bind to the ribosomal acceptor site of the 16S
rRNA cause misreading of the genetic code and inhibit
translocation in gram-negative and gram-positive bacteria
(35). Both rings I and II of the aminoglycoside are
important for its binding (36–38). Aminoglycosides also
inhibit the activity of most known ribozymes at concen-
trations much higher than that of the translation (35). The
strength of the interaction is dominated by electrostatics,
with the positively charged aminoglycosides displacing
metal ions and binding to speciﬁc sites on the structured
RNAs (35).
In contrast, the aminoglycosides tobramycin, neomycin
B, and another type of antibiotic purpuromycin have been
shown to inhibit the aminoacylation reaction at the level
of tRNA charging (39–41). Purpuromycin inhibits protein
synthesis in both prokaryotic and eukaryotic cell-free
systems (42,43), and it is evident that the inhibition
of translation is through the speciﬁc inhibition of
aminoacyl–tRNA formation (41). Neomycin B inhibits
the phenylalanylation of E. coli tRNA
Phe; one neomycin
molecule is bound to the upper part of the anticodon stem
in the yeast tRNA
Phe–aminoglycoside crystal complex
(40). Tobramycin is a potent and speciﬁc inhibitor of the
aspartylation reaction (39).
In this report, we show that pentamidine non-
speciﬁcally binds to tRNAs at concentrations much
higher than the speciﬁc binding of the known antibiotics
mentioned above. The non-speciﬁc interaction is primarily
driven by hydrophobic interactions, likely due to the
insertion of the aromatic rings into paired helices of
tRNAs, in contrast to the main role of electrostatic
interactions in the speciﬁc binding of many antibiotics to
rRNA and tRNA. Pentamidine binding has been shown
to disrupt the tRNA secondary structures and to mask the
anticodon loop of the tRNA tertiary structure in the
absence and presence of magnesium respectively, eﬀects
which are highly consistent with its inhibition of the
tRNA
Leu aminoacylation and in vitro translation.
MATERIALS AND METHODS
Materials
The E. coli tRNA
Leu (anticodon GAG) and LeuRS
(2100U/mg) used in this study were provided by
Prof. En-Duo Wang’s lab (Shanghai Institute of
Biological Sciences) (44). In each gel mobility shift assay
and footprinting experiment, tRNA was labeled at the 50
end by incorporation of [g-
32P] ATP (3000Ci/mmol;
PerkinElmer) (45). L-Leucine, ATP, tetrasodium pyro-
phosphate and dithiothreitol (DTT) were purchased from
Sigma (USA). L-[
14C] Leucine (50mCi/ml) and tetraso-
dium [
32P] pyrophosphate were products of Amersham
Biosciences.
Gel mobility shift assays
The puriﬁed 50-radiolabeled tRNA ( 0.3nM) was dena-
tured in 10mM Tris–HCl (pH 7.5) at 708C for 5min and
then slowly cooled to room temperature. An aliquot of
tRNA was incubated at 378C for 20min in 10ml gel shift
buﬀer containing varying concentrations of pentamidine,
100mM of Tris–HCl (pH 7.5), 30mM KCl and 0, 1mM,
5mM, 9mM or 12mM MgCl2 as indicated. To determine
the eﬀect of pH on pentamidine binding, the following
buﬀers at a concentration of 100mM were used: sodium
cacodylate for pH 6.0 and 6.5, Tris–HCl for 7.0, 7.5 and
8.5. Samples were then chilled on ice and analyzed by
electrophoresis on 20% non-denaturing polyacrylamide
gels in 1  TB buﬀer (0.045M Tris–borate) at 48C with a
voltage gradient of 12–15V/cm. The gels were exposed to
Phosphor screens that were scanned and analyzed using a
variable scanner Typhoon 9200 (Amersham Pharmacia
biotech). Data were plotted using the program GraphPad
Prism 4.0.
T1ribonuclease footprinting
The 50-end-labeled tRNA was cleaved by ribonuclease T1
and hydroxyl radical to probe the interaction between
pentamidine and tRNA. T1 footprinting was performed as
described previously (45). An aliquot of the pre-denatured
tRNA was incubated in 18ml gel shift buﬀer containing
the desired concentrations of pentamidine at 378C for
20min. RNase T1 (2mlo f1 0 U / ml) was then added to
initiate the T1 cleavage reaction at 378C for 10s, and
stopped by adding 20ml of phenol–chloroform (1:1) and
vigorous vortexing. After centrifugation, 16ml of super-
natant was removed for electrophoresis on 12% poly-
acylamide/7M urea sequencing gels. Control lanes were
digested with the indicated buﬀer or enzymes under
denaturing conditions.
Isothermal titration calorimetry (ITC)
ITC measurements were carried out at 378C using a
VP-ITC calorimeter (MicroCal, Northampton, MA) with
stirring at 400rpm. In a typical experiment, 1.43ml of
0.01mM total yeast tRNAs purchased from Sigma (USA)
was titrated with 10mM of pentamidine (28 injection of
5ml each). The buﬀer contained 10mM Hepes (PH 7.5)
and 300mM NaCl with or without 5mM magnesium. To
correct for the dilution and mixing eﬀects, a series of
control injections was carried out in which pentamidine
was injected into the buﬀer alone. The heat signal of this
control was then subsequently subtracted from the raw
data for each injection experiment. MicroCal ORIGIN
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for data acquisition and analysis.
Aminoacylation experiments
The tRNA
Leu aminoacylation tests were assessed as
described previously (46), and performed at 378Ci na
20ml reaction mix containing 100mM Tris–HCl (pH 7.8),
30mM KCl, 12mM MgCl2, 4mM ATP, 0.1mM EDTA,
0.5mM DTT, 0.1mM [
14C] leucine (50mCi/ml), 1mM
E. coli LeuRS, 3.85mM tRNA
Leu (pre-denatured) and
the indicated concentrations of pentamidine. The mix
except for LeuRS was incubated at 378C for 10min and
LeuRS was then added to initiate the aminoacylation
reaction. After a 30min of reaction, the samples were
applied to Whatman Grade 3 qualitative ﬁlter paper,
precipitated with 5% trichloroacetic acid (TCA), washed
with 5% TCA and ethanol, and analyzed by scintillation
counting.
Adenylateformation assay
The [
32P] PPi-ATP exchange activity of E. coli LeuRS was
assayed in 100mM HEPES–KOH (pH7.8), 10mM
MgCl2, 10mM KF, 4mM ATP, 2mM [
32P] pyropho-
sphate, 1mM L-Leucine, and 4nM LeuRS (47). The
analysis was carried out similar as in the aminoacylation
reactions, except that 4min of reaction was run after
adding LeuRS.
Invitro translation assays
An assay of protein synthesis in vitro was performed using
Flexi rabbit reticulocyte lysate (Promega) according to the
manufacturer’s instruction with the following modiﬁca-
tions: Luciferase control RNA (1mg/ml) was mixed with
reticulocyte lysate on ice and then separated into aliquots
for translation at 308C for 90min in a ﬁnal reaction
volume of 5ml containing 20mM amino acid complete
mixtures, 70mM KCl, varying concentrations of penta-
midine and 1.35mM, 2.5mM or 3.5mM magnesium
acetate. Then 1ml of the luciferase translation reaction was
removed for bioluminescence assay using a Luminometer
TD-20/20 (Turner Designs). Data were plotted using
Graphpad Prism. Control reactions were performed in the
same condition except that pentamidine was added after
the translation.
RESULTS
Pentamidine binds to tRNA cooperatively
Although pentamidine binds to group I ribozyme RNA
and inhibits ribozyme function, we found no evidence that
this compound, at a concentration of up to 1mM, binds to
single-strand RNA, DNA oligomers and double-strand
DNA using similar measuring conditions (data not
shown). This result indicated that pentamidine has a
lower binding aﬃnity with DNA and non-structured
RNA, which is consistent with a model that pentamidine
inhibition of the translation in yeast mitochondria occurs
through its binding with the two major classes of
structured RNAs, tRNA and rRNAs. In this study,
we aimed to explore if pentamidine interacts with tRNA;
and if it does, how this interaction impacts the function of
tRNA charging and translation.
Native PAGE gel analysis was used to examine if
pentamidine binds to pure tRNA molecules (Figure 1)
in vitro. As shown in Figure 2A, a substantial shift of
tRNA
Leu to a slower mobilized RNA species was observed
at 100mM of pentamidine in the absence of magnesium,
and 400mM of the drug saturated the binding, suggesting
that pentamidine binds to tRNA eﬃciently. Interestingly,
the binding aﬃnity was dose-dependently decreased by
magnesium (Figure 2B and Table 2). This ﬁnding is
consistent with the previous conclusion that the charge
interaction between pentamidine and structured RNA
contributes to its binding with the group I intron ribozyme
(28,31). Consistently, pentamidine binding was increased
with pH in the absence of magnesium, displaying the
contribution of electrostatic interaction between pentami-
dine and tRNA; while this change was not observed in
the presence of 5mM Mg
2+ that presumably overrides
the electrostatic interaction imposed by pentamidine
(Figure 2C). It should be noted that the majority of the
pentamidine-bound tRNA remained in the gel wells
and did not run into the gel, probably because of the
neutralization of the negative charge of tRNA by multiple
pentamidine binding.
Figure 1. Structures of E. coli tRNA
Leu (A) and pentamidine (B).
The secondary structure of E. coli tRNA
Leu showing main tertiary
interactions is revised from (46); Numbering of nucleotides as
well as nomenclature of modiﬁed nucleotides are according to Sprinzl
et al. (52).
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highly cooperative fashion, and the Hill coeﬃcient
indicative of cooperativity was signiﬁcantly increased by
higher concentrations of magnesium, from 3.1 without
Mg
2+ to 8.3 with 12mM Mg
2+ (Table 2). Clearly,
magnesium increases not only the required concentrations
of pentamidine to bind to tRNA, but also the binding
cooperativity. This indicates that when tRNA folds to
a more compacted structure, it becomes less accessible to
pentamidine. Furthermore, the drug interacts with folded
tRNA in a manner signiﬁcantly diﬀerent from tRNA that
is not folded.
Pentamidine binding disrupts the tRNAsecondary
structureandmaskstheanticodonloopofthetertiarystructure
T1 ribonuclease footprinting experiments were then
performed to address how pentamidine binding aﬀects
the tRNA structure (Figure 3A). RNase T1 ribonuclease
speciﬁcally cleaves the single-stranded RNA at the 30 of
each guanosine residue and has been used to detect the
unpaired guanosine located on the accessible surface of
large structured RNAs (45,48,49).
In the absence of magnesium, all Gs in the stem regions
of tRNA
Leu were not susceptible to T1 cleavage, indicat-
ing the formation of secondary structure. Interestingly,
G59 in the TcC loop was resistant to T1 cleavage as well,
indicating that this loop might adopt some kind of
conformation to prevent G59 from being accessed by T1
ribonuclease. G sites in the D loop and anticodon loop
were cleaved by T1 ribonuclease, with the cleavage at G34
and G36 in the GAG anticodon being about 10-fold
stronger than that in the D-loop. G37 was not cleaved by
T1 ribonuclease, probably because the followed pseudour-
idine c38 alters its conformation to one not recognized by
T1. When 12mM Mg
2+ was present, complete protection
of Gs in the D loop from T1 ribonuclease attack was
evident, consistent with the knowledge that tRNA readily
adopts its L-shape tertiary structure at this magnesium
concentration. The supersensitive nature of G34 and G36
in the anticodon loop was evident in the absence and
presence of magnesium, which has two important
implications. First, it is consistent with the requirement
for the extreme extended conformation that anticodon
bases must adopt to interact with corresponding codon.
Second, the tRNA secondary structure might adopt some
kind of conformation in the absence of magnesium,
resulting in a D loop structure that is much less accessible
to T1 cleavage than the extended anticodon loop.
Remarkably, the presence of pentamidine (>100mM) in
the tRNA samples containing no magnesium strongly
protected G34 and G36 in the anticodon loop from being
cleaved by T1, resulting in sensitivity similar to the
D-loop, which suggested that pentamidine binding to
tRNA reduces T1 accessibility (Figure 3A and 3B).
Meanwhile, all Gs in the base-paired stem loops became
accessible to T1 ribonuclease, and the accessibility was
equivalent to that in the D and anticodon loops
(Figure 3A and 3C). These results indicated that penta-
midine binding strongly relaxes the preliminary tRNA
structure formed in Tris–HCl, and each G residue in the
relaxed structure is similarly accessible to T1 ribonuclease.
In the presence of 12mM Mg
2+, up to 400mM penta-
midine did not impose an observable eﬀect on the
T1-detectable tRNA structure, while the drug at 600mM
nearly completely protected G34 and G36 in the anti-
codon loop from T1 cleavage, consistent with the sharp
increased tRNA-binding ability at the same pentamidine
concentration shown in the gel-shift assay (Figure 2).
Figure 2. Gel retardation assay of pentamidine binding to tRNA
Leu.
A ﬁxed concentration of
32P-labeled tRNA
Leu was incubated with the
indicated concentrations of pentamidine in the absence magnesium (A),
diﬀerent concentrations of magnesium (B) at pH 7.5, and diﬀerent pH
in the absence and presence of 5mM magnesium (C). The shifted bands
were quantiﬁed by PhosphorImager analysis and plotted. The EC50s
and Hill coeﬃcients are listed in Table 2. White misting precipitation
started to appear when pentamidine concentration reached 1mM. The
shifted fraction of input tRNA was calculated and plotted against the
logarithm of pentamidine concentrations by ﬁtting to a Hill equation
Y=Bottom+(Top Bottom)/(1+10
[(Log EC50 X) Hillslope]). EC50
indicates the eﬀective pentamidine concentration causing 50% of
tRNA to shift. The inserts in (B) show the results of plotting EC50s
against diﬀerent magnesium concentrations.
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not accompanied by an increased cleavage at any other
region of tRNA, suggesting pentamidine could not disrupt
the tRNA tertiary structure as it did to the secondary
structure (no Mg
2+). Nevertheless, pentamidine binding
very likely alters the tRNA tertiary structure, which is
featured by masking its anticodon codon; this binding
eﬀect is anticipated to interfere with the tRNA function.
Since T1 ribonuclease is powerless to detect pentami-
dine binding to the base-paired regions of tRNA, free
radical footprinting method detecting the accessibility
of the RNA backbone was employed to study the
pentamidine-binding sites on tRNA
Leu (Supplementary
Figure S1). Consistent with the model that the tRNA
tertiary structure is established by the closing of the D and
TcC loops through tertiary interactions, TcC loop and
the D loop were drastically protected from the free radical
attack in the folded structure. In the absence of
magnesium, as low as 10mM pentamidine signiﬁcantly
protected the tRNA secondary structure from being
attacked by free radicals, and  50mM pentamidine
protected almost the entire RNA phosphate backbone
except for a few sites in TcC stem and the variable stem
from free radical cleavage, indicating that pentamidine
binding protects the tRNA backbone from being attacked
by free radicals. In the presence of magnesium, 400mM
pentamidine was required to reach the near complete
protection.
Clearly, free hydroxyl radical footprinting was much
more sensitive in detecting the pentamidine–tRNA inter-
action than was T1 footprinting and gel-shift assay in this
study. Hydroxyl radical footprinting was used to study the
pentamidine–DNA interaction previously, showing that
pentamidine at a concentration up to 100mM only grants
a limited protection to DNA backbone at certain AT-rich
regions (50). Obviously, pentamidine protection of
tRNA
Leu from free radical attack completely diﬀered
from its DNA protection pattern. The tRNA protection
seemed to be equivalently eﬀective at each free radical-
accessible site regardless of the presence or absence of
magnesium, and the protection pattern was much more
eﬀective and quite uniform along the tRNA backbone.
This observation strongly suggests that pentamidine
binding of tRNA is not sequence-speciﬁc or site-speciﬁc.
Pentamidine binding islargely driven bynon-specific
hydrophobic interactions
ITC has become an important tool for the direct and
reliable measurement of the thermodynamic parameters of
the interaction of small molecules with biopolymers (51).
This method was used here to directly determine the
Figure 3. Pentamidine binding alters the sensitivity of tRNA to ribonuclease T1 cleavage. The radiolabeled tRNA was preincubated with the
indicated concentrations of pentamidine and MgCl2 at 378C for 20min; ribonuclease T1 was then added to partially digest tRNA and the resulted
RNA fragments were fractionated by PAGE on an 12% polyacrylamide/7M urea gels. One representative gel is shown in (A). Nucleotides and their
corresponding locations stems in the tRNA secondary structure are indicated on the left of the gel. Lane T1 indicates tRNA sample partially digested
by T1 ribonuclease under denaturing conditions. (B) The protection at G34 and G36 was determined and ﬁt to a Hill equation as in Figure 2.
(C) The protection at some other positions including G12at D stem, G13at D loop, G43at anticodon stem, Ge22at Variable stem and G64 at
T stem in the absence of magnesium were also determined and plotted.
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pentamidine and tRNA. Figure 4A shows that the
ITC proﬁles for the binding of pentamidine to tRNA
with 0 and 5mM Mg
2+ are both biphasic, consistent
with the presence of two binding equilibria. Therefore,
the ITC results were best ﬁtted by using a model of
two sets of binding sites using Origin 7 (Figure 4B).
The thermodynamic parameters are presented in Table 1.
The enthalpies, entropies and free energies are shown in
Figure 4C.
Table 1 shows that the binding constant (K) for the ﬁrst
equilibrium (K1) was greater than that for the second (K2).
In the absence of magnesium, K1 was 533-fold higher than
K2; in the presence of magnesium, K1 was 15-fold higher
than K2. The drastically larger K1 as compared to K2
indicates that the ﬁrst class of binding sites determines the
binding aﬃnity of pentamidine with tRNA. Consistent
with the hydroxyl radical footprinting result showing the
non-speciﬁc binding of pentamidine to tRNA, ITC
measurements demonstrated evidence for a large number
of pentamidine-binding sites on tRNA: In the unfolded
tRNA, 26 Class I binding sites and 41 Class II binding
sites were present. In the folded tRNA, the Class I and
Class II binding sites were increased to 56 and 52,
respectively.
Class I binding sites responded to magnesium very
sensitively, with K1 decreasing about 100-fold and the
binding sites doubling, while Class II binding sites were
much less sensitive (Table 1). Figure 4C and Table 1 show
that H was a small positive number for Class I binding
sites, indicating that enthalpic interactions including
hydrogen bond formation, charge interaction and van
der Waal’s interactions between pentamidine and tRNA
were unfavorable. A large positive TS indicated
entropically favorable binding and suggested that hydro-
phobic interactions are the main driving force for the
Class I binding of pentamidine to tRNA, which is also
consistent with the non-speciﬁc feature of pentamidine
binding.
Pentamidine contains two aromatic rings linked by an
alkyl chain. Insertion of the aromatic rings into the double
helix of tRNA is expected to result in a strong
hydrophobic interaction. About 22–30bp are generally
present in the unfolded cloverleaf structure of tRNAs
(52); (http://lowelab.ucsc.edu/GtRNAdb/Scere/Scere-align.
html). If each pentamidine molecule is inserted between
two neighboring base pairs, the average binding sites
provided by the total yeast tRNAs should be very close
to 26, the number of evident Class I binding sites.
Considering that the base-paired helical structures are
very ﬂexible in the unfolded tRNAs, it could be very
possible for both of the aromatic rings of pentamidine to
be inserted into the same neighboring base pairs, with
each aromatic ring being stacked with one pair of the
neighboring bases (Figure 5A). It is conceivable that this
deep insertion can disrupt the hydrogen bonds of each
base pair in the tRNA secondary structure, explaining
the universal T1 accessibility to all Gs in tRNA
Leu under
the saturated concentrations of pentamidine. The tRNA
folds to a more compact structure in magnesium with
additional base paires formed between the D loop and
the TcC loop. The geometry of the helix of the folded
tRNAs is strongly restricted, and insertion of both
aromatic rings of the pentamidine into the neighboring
base pairs should not be allowed. Because the hydro-
phobic interaction/entropy change is also the only
driving force for pentamidine binding to Class I sites
on the folded tRNA, we propose that each pentamidine
molecule may form a much weaker hydrophobic inter-
action with the base paired helix through one of its
aromatic rings, consistent with its 100-fold lower binding
constant and 2.2 times more binding sites (Figure 5B).
Class II binding was apparently driven by both
favorable entropy and favorable enthalpy changes
(Figure 4C), consistent with the previous ﬁnding that the
charge interaction between positively charged pentamidine
and negatively charged phosphate in tRNA contributes to
their interaction (28). Class II binding sites were not
as sensitive to magnesium-mediated tRNA folding as
the Class I sites, with K2 decreasing to one third and the
binding sites increasing by one fourth. Although the
charge attraction between the drug and tRNA obviously
did not contribute much to the interaction energetically,
the close-distance attraction between diﬀerently charged
molecules could play a large role in facilitating base
stacking interactions (Figure 5C). Therefore, it is very
likely that Class I and Class II binding sites on tRNA are
close to each other. Consistently, the Class II binding sites
numbered 41 and 52 in the absence and presence of
magnesium, respectively, which are close to that of the
Class I binding sites in the presence of magnesium. It is
obvious that not all phosphate units in tRNA can serve as
Class II binding sites. It is very possible that only the
phosphate backbone of the base-paired regions of tRNAs
participates the Class II binding, consistent with the
ﬁnding that pentamidine did not bind to the single
stranded RNA (data not shown). These ﬁndings suggested
a model in which the charge interaction-driven Class II
binding draws pentamidine to a close proximity with
tRNA, and then insertion of the aromatic ring of
pentamidine into the double helix of tRNA stabilizes the
charge interaction by a large entropy change (Figure 5).
Pentamidine binding inhibits tRNA
Leuaminoacylation
We then asked if the non-speciﬁc binding of pentamidine
to tRNA aﬀected the tRNA charging process. The ability
of tRNA
Leu to accept [
14C] leucine, catalyzed by its
cognate tRNA synthetase LeuRS, was studied as a
function of increasing concentrations of pentamidine.
MgCl2 at 12mM was included in each reaction because
LeuRS-catalyzed tRNA
Leu charging is very active at this
concentration (46). As shown in Figure 6, leucylation of
tRNA
Leu was decreased dose-dependently with increased
concentrations of pentamidine (0–1.5mM). Data were
ﬁtted well to the sigmoidal dose-response (variable slope)
equation, resulting in an inhibitory concentration and
cooperativity of inhibition very similar to those of T1
footprinting and gel-shift analysis (Table 2). These results
strongly suggest that the extensive non-speciﬁc pentami-
dine binding converts the tRNA
Leu to an inactive
structure not recognized by LeuRS.
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LeuRS forms an activated leucyl–adenylate using ATP as
a substrate in the absence of tRNA
Leu. Pyrophosphate
[PPi] exchange experiments were performed to examine if
the adenylation of leucine by LeuRS was interfered by
pentamidine. It is showed that pyrophosphate exchange at
all pentamidine concentrations from 100 to 1500mM was
at the same level (Figure 6, insert), indicating that
pentamidine does not act as a structural analogue of
ATP in the aminoacylation reaction and does not interfere
with the catalytic activity of LeuRS itself during the amino
acid activation step. This conclusion was further sup-
ported by the aminoacylation experiment with increasing
ATP concentrations, which showed that the inhibitory
eﬀect of pentamidine was identical under diﬀerent ATP
concentrations (data not shown).
Pentamidine binding inhibitsthe invitro translation
The luciferase mRNA was translated in an in vitro
translation system to address whether pentamidine inhi-
bits translation in vitro. Pentamidine dose-dependently
reduced the ﬂuorescence emission from the translation
reactions, and the increase of magnesium concentration
elevated the pentamidine requirement (Figure 7 and
Table 2). Pentamidine itself did not quench the ﬂuores-
cence resulting from luciferase activity (Figure 7, insert).
Therefore, the reduced ﬂuorescence intensity was attrib-
uted to the inhibition of productive translation, likely due
to pentamidine interfering with tRNA structure-related
functions such as charging and docking, and possibly
rRNA structure-related functions including catalysis and
ribosome assembly.
DISCUSSION
Pentamidine has been used clinically for over a half of
century, and it becomes clear now that pentamidine is
selectively accumulated by pathogenic protozoa through
high aﬃnity transporters located in the pathogen mem-
branes (6). However, its mechanism of actions inside of
cells remains perplexing. Our recent ﬁnding that 1mM
pentamidine in the growth media of S. cerevisiae leads to a
near complete inhibition of the mitochondrial translation,
while up to 25mM of the drug has no eﬀect on the levels of
the cytoplasmic translation, sheds new light on pentami-
dine targets in vivo (30).
Pentamidine binding totRNA inhibits tRNA
aminoacylation and translation
In this study, we have showed that pentamidine binds to
tRNAs at concentrations comparable to that of the
Candida group I intron (31). The binding disrupts the
tRNA secondary structure formed in the absence of
magnesium. In the presence of magnesium, pentamidine
uniformly binds to the folded tRNA as well and masks the
anticodon loop, but with a greatly reduced aﬃnity. The
crystal structure of the complex between leucyl–tRNA
synthetase and tRNA
Leu points that the synthetase
recognizes its cognate tRNA depending essentially on
tRNA shape rather than base-speciﬁc interactions (53).
Consistent with this view, pentamidine inhibition of
tRNA aminoacylation can be explained by the distorted
Table 1. Thermodynamic parameters for pentamidine binding to tRNA
tRNA Binding site NK (M
 1) H (kcalmol
 1) TS (kcalmol
 1) G (kcalmol
 1)
Without Mg
2+ 1 26.0 0.3 (8.0 5.7) 10
7 0.44 0.05 11.66  11.23 0.05
2 41.1 0.8 (1.5 0.3) 10
5  2.79 0.08 4.56  7.35 0.08
5mM Mg
2+ 1 56.4 2.7 (8.0 4.2) 10
5 0.27 0.08 8.65  8.39 0.08
2 51.5 4.7 (5.2 1.5) 10
4  2.00 0.27 4.68  6.69 0.27
Figure 4. ITC proﬁles at 378C for the titration of pentamidine with a
solution of tRNA containing no MgCl2 (I) or 5mM MgCl2 (II). Each
heat burst curve in panel A is the result of an injection of pentamidine
into a tRNA solution. The corrected injection heats shown in (B) were
derived by integration of the corresponding heat burst curves shown in
(A), followed by subtraction of the corresponding dilution heats derived
from control titrations of the drug into buﬀer containing no tRNA.
The data points in panel B reﬂect the corrected experimental injection
heats, while the solid lines reﬂect the calculated ﬁts of the data via a
model for two independent sets of binding sites. (C) shows the
thermodynamic signatures for the binding events, and 1 and 2 represent
the Class I and Class II binding sites, respectively.
1660 Nucleic Acids Research, 2008, Vol. 36, No. 5tRNA structure induced by extensive drug binding. The
eﬀects of pentamidine in inhibiting tRNA aminoacylation
and in distorting the anticodon loop explain the potent
activity of protein translation in vitro and in vivo
(Figure 8). Therefore, tRNA is the second class of
pentamidine-bound structured RNAs whose biological
functions are hindered by pentamidine binding.
Although the expected targets of pentamidine in yeast
are mitochondrial tRNAs while this study has used E. coli
tRNA
Leu and yeast total tRNAs as model. However, the
in vitro ﬁndings are believed to be in vivo relevant for two
reasons: ﬁrst, the global architecture of tRNAs is highly
conserved; second, this study shows that the interaction
between pentamidine and tRNA is non-speciﬁc to any
tRNA sequence. We noticed that about two orders of
magnitude higher concentrations of pentamidine are
required to inhibit protein translation in vitro (EC50 of
204.4mM) than that in living S. cerevisae ( 90% inhibi-
tion at 1mM). This large diﬀerence can be readily
explained by the drug accumulation capability of
Figure 5. Proposed binding modes of pentamidine to tRNA. (A) In the
absence of magnesium ions, one pentamidine molecule is stacked
between 1bp of the ﬂexible tRNA secondary structure. This insertion
should at least partially disrupt the hydrogen bonds between each base
pair, and thus blockers are placed between each hydrogen pair of bond
donor and receptor to illustrate this possible outcome. (B) In the
presence of magnesium, two pentamidine molecules are stacked
between base pairs of the compact tRNA tertiary structure, in which
only one phenyl group inserts in between the base pairs and the other
ﬂoats outside because of the structure constraints. (C) Positively
charged pentamidine experiences a charge interaction with negatively
charged phosphate in the absence and presence of magnesium.
Figure 6. Pentamidine inhibits aminoacylation of tRNA
Leu in vitro. The
activity of tRNA
Leu synthetase (LeuRS) in charging E. coli tRNA
Leu and
adenylating L-Leucine were measured at increasing concentrations of
pentamidine as described in Materials and Methods. PPi-ATP exchange
reaction was used to reﬂect the adenylation activity of LeuRS. (A) The
relative activity of LeuRS to charge tRNA
Leu at each pentamidine
concentration was obtained using the charging activity displayed by the
tRNA sample receiving no pentamidine as a control; the relative charging
activity was then plotted against pentamidine concentrations as in
Figure 2. The solid line (EC50 681.5mM) and dashed line (EC50 759.8mM)
indicates the experiment performed using tRNA with and without pre-
denaturation treatment, respectively. (B) The PPi-ATP exchange activity
of LeuRS was plotted against each pentamidine concentration.
Table 2. Hill analysis results of diﬀerent experiments
Mg
2+ (mM) Hill coeﬃcient EC50 (mM)
Native gel analysis
0 3.1 158.3
1 5.8 218.7
5 8.1 381.4
9 7.4 621.0
12 8.3 785.1
T1 footprinting
0 4.9 161.3
12 6.3 409.8
Leucylation assay
12 8.2 681.5
12
a 11.7 759.8
In vitro translation
1.35 6.9 204.4
2.5 34.5 425.4
3.5 14.7 470.0
Hill analysis is described in the legend to Figure 2, and EC50 indicates
the eﬀective pentamidine concentration causing 50% of inhibition.
aIndicates the assay in which tRNA was not pre-denatured.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1661pathogenic fungi and protozoans. For example, pentami-
dine is concentrated in trypanosomes up to 1.1mM after a
3h incubation with 1mM of pentamidine (54). Therefore,
it is reasonable to predict that the intracellular concentra-
tion of pentamidine into mitochondria could reach near
millimolar concentrations to inhibit translation.
The mechanismof pentamidine binding to structured
RNAs: pentamidine binds totRNA non-specifically
andthe bindingis driven by hydrophobic interactions
Aminoglycosides represent a major class of translation
inhibitors that speciﬁcally binds to their targets through
electrostatic interactions. In contrast, this study reveals
that pentamidine binds to tRNAs non-speciﬁcally and
primarily through hydrophobic interactions. This non-
speciﬁc interaction is consistent with its much lower
binding aﬃnity compared to that of aminoglycosides.
Two classes of pentamidine-binding sites are present on
tRNAs, and each class contains dozens of distinct sites.
Class I binding sites are located in the stacked bases of the
tRNA double helix, and the negatively charged phosphate
backbone provides for Class II binding sites. Remarkably,
Class I binding sites determine the binding aﬃnity
between pentamidine and tRNA. Hydrophobic interac-
tions are the main driving force for both classes of
binding. Although cation competition experiments shown
in this study and some previous reports suggest that
electrostatic interaction play an role in pentamidine
binding of its RNA target (28,30), ITC experiments in
this report clearly show that the charge attraction did not
contribute much to the binding energetically. We pro-
posed a model in which the ﬂat and rigid phenyl rings of
pentamidine are capable of inserting into the stacked bases
of RNA double helices, resulting in hydrophobic stacking
interactions (Figure 5). The function of multivalent
cations in weakening pentamidine’s eﬀect can be attrib-
uted to the capability of cations in supporting the folding
of structured RNAs, which reduces the pentamidine-
binding aﬃnity to Class I sites on tRNAs. It is also
possible that the charge interaction plays a role in
facilitating the base stacking interactions by attracting
these two diﬀerently charged molecules to a close distance
(Figure 5C).
Structured RNAs may be themajor molecular targets
of pentamidine: implication fordeveloping more effective
pentamidine derivatives
Mitochondria are the primary cellular targets of penta-
midine in pathogenic eukaryotes and in experimental
model eukaryotes (55,56). Resistance to pentamidine in
L. mexicana is accompanied by the lack of mitochondrial
accumulation of the drug, and pentamidine is conse-
quently excluded from the parasite (57). Mitochondrial
translation occurs inside of mitochondria in which the
structured RNAs including tRNA and rRNA are present
at much higher concentrations than the low-copy DNA
genomes. Our ﬁnding that pentamidine binding to
structured RNAs is governed by non-speciﬁc hydrophobic
interactions predicts that, in addition to tRNAs, rRNAs
are important targets of pentamidine as well. We also
found that pentamidine binds to large structured RNAs at
a much higher aﬃnity than to DNA and single-stranded
RNA (data not shown), possibly because the rigid double
helical structure of DNA does not favor pentamidine
insertion into the stacked bases and ssRNA lacks base
paired helical structure for hydrophobic interaction with
pentamidine. The higher binding aﬃnity of pentamidine
with RNA over DNA is also supported by the observation
that pentamidine concentrations that repress mitochon-
drial translation have no eﬀect on the steady-state levels of
the mitochondrial mRNAs, which are products of
transcription from DNA (30). Therefore, we propose
that structured RNAs are the dominant binding targets of
pentamidine in mitochondria. Importantly, the ﬁnding
that pentamidine binds to tRNAs and very likely to
rRNAs as well, exerting a strong inhibition of mitochon-
drial translation, explains the pentamidine-induced inter-
ruption of many aspects of mitochondrial function and
morphology.
Figure 7. Pentamidine inhibits proteins synthesis in vitro. Luciferase
mRNA was translated in PROMEGA Flexi rabbit reticulocyte lysate
reagents with increasing concentrations of pentamidine at diﬀerent
concentrations of magnesium, and the enzymatic activity of the
translated luciferase was measured by a luminometer and plotted
as in Figure 6. EC50 at each magnesium concentration was listed.
Please be noted that the luciferase activity varied greatly with
magnesium concentrations; the activity at 1.35mM, 2.5mM and
3.5mM magnesium was 8515.0, 1773.0 and 193.7 counts, respectively.
The insert shows the results of the control reactions in which
pentamidine was added to each sample after the translation reaction
was ﬁnished.
Figure 8. Scheme of the inhibition of tRNA aminoacylation and
translation by pentamidine. Magnesium ions help tRNAs fold to their
native structures, containing the identity elements that cognate aaRS
recognizes. The aminoacylated tRNA then participate in translation.
Pentamidine binds to tRNAs non-speciﬁcally. If the unfolded tRNAs
are bound by pentamidine, the binding disrupts the tRNA secondary
structure and the subsequent folding and function. When pentamidine
binds to the folded tRNAs, the three dimensional structure of tRNAs is
distorted and the anticodon loop is masked, preventing tRNA from
being charged by its cognate aaRS, leading tRNA oﬀ its functional
pathway.
1662 Nucleic Acids Research, 2008, Vol. 36, No. 5Although Trypanosome and Leishmania accumulate
pentamidine to a much greater extent than host cells, a
certain amount of pentamidine is still expected to be
uptaken into host cells. Pentamidine inhibition of transla-
tion through binding to tRNAs and possibly rRNAs
through a non-speciﬁc hydrophobic interaction also
explains the side eﬀects of this drug, since pentamidine
has no selectivity mechanism to discriminate human and
the pathogenic RNAs.
The RNA-binding mechanism of pentamidine revealed
in this study shed lights on a target-based approach
for designing novel and more speciﬁc aromatic diamidines
to combat microbial infections through targeting the
mitochondrial or kinetoplast translation in pathogenic
fungi and protozoans including Pneumocystis carinii,
Trypanosome, Leishmania, and Entamoeba histolytica.
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